Theodore R. Samuels II
Theodore R. Samuels II's purchase track record
How the stock did after each of Theodore R. Samuels II's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/28/2025 | CNC | $249K | +23.4% | +72.3% | +8.8% |
| 12/13/2024 | CNC | $294K | -2.1% | -7.1% | -1.2% |
| 11/20/2023 | BMY | $423K | +3.1% | -9.3% | +16.7% |
| 2/8/2023 | CNC | $503K | -8.3% | -9.8% | +8.5% |
| 4/28/2022 | CNC | $507K | +13.2% | +3.0% | -11.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
AI boom boosts IRM as REITs gain from data demand. Iron Mountain is highlighted in a Yahoo article that links the rapid growth of AI to increased demand for data center space, benefiting several REITs including IRM. The company also announced its third‑quarter 2026 earnings release and conference call, giving investors a chance to review its performance. A separate piece noted that REITs overall are outperforming the market, which may support IRM’s position in the sector.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Perrigo valuation seen as cheap but burdened by high debt. A recent Seeking Alpha article notes that Perrigo's shares appear cheap compared with peers. The piece highlights that the company carries a sizable debt load, which could limit financial flexibility. This contrast may lead investors to weigh the low valuation against the debt risk when evaluating the company.
Transaction History
| CNC | ▲ Buy | Grant | 583 | $0 | 9/30/2026 | View on chart |
| CNC | ▲ Buy | Grant | 465 | $0 | 6/30/2026 | View on chart |
| CNC | ▲ Buy | Grant | 3,992 | $0 | 5/12/2026 | View on chart |
| CNC | ▲ Buy | Grant | 943 | $0 | 3/31/2026 | View on chart |
| CNC | ▲ Buy | Grant | 608 | $0 | 12/31/2025 | View on chart |
| CNC | ▲ Buy | Grant | 710 | $0 | 9/30/2025 | View on chart |
| CNC | ▲ Buy | Open Market | 9,000 | $249K | 7/28/2025 | View on chart |
| CNC | ▲ Buy | Grant | 463 | $0 | 6/30/2025 | View on chart |
| CNC | ▲ Buy | Grant | 3,579 | $0 | 5/13/2025 | View on chart |
| CNC | ▲ Buy | Grant | 416 | $0 | 3/31/2025 | View on chart |
| CNC | ▲ Buy | Grant | 414 | $0 | 12/31/2024 | View on chart |
| CNC | ▲ Buy | Open Market | 5,000 | $294K | 12/13/2024 | View on chart |
| CNC | ▲ Buy | Grant | 335 | $0 | 9/30/2024 | View on chart |
| CNC | ▲ Buy | Grant | 377 | $0 | 6/30/2024 | View on chart |
| CNC | ▲ Buy | Grant | 2,916 | $0 | 5/14/2024 | View on chart |
| CNC | ▲ Buy | Grant | 324 | $0 | 3/31/2024 | View on chart |
| CNC | ▲ Buy | Grant | 433 | $0 | 12/31/2023 | View on chart |
| BMY | ▲ Buy | Open Market | 8,500 | $423K | 11/20/2023 | View on chart |
| CNC | ▲ Buy | Grant | 470 | $0 | 9/30/2023 | View on chart |
| IRM | ▲ Buy | Grant | 2,264 | $23 | 7/17/2023 | View on chart |
| CNC | ▲ Buy | Grant | 469 | $0 | 6/30/2023 | View on chart |
| CNC | ▲ Buy | Grant | 2,947 | $0 | 5/10/2023 | View on chart |
| CNC | ▲ Buy | Grant | 440 | $0 | 3/31/2023 | View on chart |
| CNC | ▼ Sell | Other | 300 | $0 | 3/22/2023 | View on chart |
| CNC | ▲ Buy | Open Market | 7,000 | $503K | 2/8/2023 | View on chart |
| CNC | ▲ Buy | Grant | 383 | $0 | 12/31/2022 | View on chart |
| CNC | ▲ Buy | Grant | 350 | $0 | 9/30/2022 | View on chart |
| CNC | ▲ Buy | Grant | 376 | $0 | 6/30/2022 | View on chart |
| PRGO | ▲ Buy | Option Exercise | 6,599 | $255K | 5/17/2022 | View on chart |
| CNC | ▲ Buy | Open Market | 6,270 | $507K | 4/28/2022 | View on chart |
| CNC | ▲ Buy | Grant | 2,323 | $0 | 4/26/2022 | View on chart |
| CNC | ▲ Buy | Grant | 381 | $31K | 3/31/2022 | View on chart |
| CNC | ▲ Buy | Grant | 1,100 | $0 | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Centene Expands CHOICE Arrangements in Indiana, Ohio, Oklahoma
Centene has rolled out new benefit programs that support its CHOICE arrangements in Indiana, Ohio and Oklahoma, signaling a push to broaden its managed care footprint. Analysts note the company’s turnaround still has room to grow, and its target price remains well above the current level. The broader managed‑care landscape is also shifting, with UnitedHealth reporting higher margins but lower membership, a trend that may influence competitive dynamics.
Centene Expands CHOICE Arrangements in Indiana, Ohio, Oklahoma. Centene has rolled out new benefit programs that support its CHOICE arrangements in Indiana, Ohio and Oklahoma, signaling a push to broaden its managed care footprint. Analysts note the company’s turnaround still has room to grow, and its target price remains well above the current level. The broader managed‑care landscape is also shifting, with UnitedHealth reporting higher margins but lower membership, a trend that may influence competitive dynamics.